TAILIEUCHUNG - Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant efusion in children with solid tumors or lymphoma

Currently, no available coherent management protocol exists for pediatric cancers associated with pleural effusion, ascites, and pericardial efusion. This study aimed to retrospectively present our experience in treating pediatric cancer patients with pleural effusion, ascites, and pericardial efusion using interleukin-2 (IL-2) and dexa‑ methasone (DEX) intracavitary injections. | Zhang et al. BMC Cancer 2021 21 1302 https s12885-021-09041-7 RESEARCH Open Access Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma Yu Tong Zhang1 Xiao dan Zhong1 Yan li Gao2 and Jian Chang1 Abstract Background Currently no available coherent management protocol exists for pediatric cancers associated with pleural effusion ascites and pericardial effusion. This study aimed to retrospectively present our experience in treating pediatric cancer patients with pleural effusion ascites and pericardial effusion using interleukin-2 IL-2 and dexa methasone DEX intracavitary injections. Methods Between January 1st 2008 and December 31st 2020 medical reports of patients diagnosed with solid tumors or lymphoma were checked to identify patients diagnosed with gt 2 cm pleural effusion and or more than grade 1 ascites and or more than small pericardial effusion. Patients diagnosed with effusions and treated with IL-2 and DEX were identified as being in the effusion group. Meanwhile patients with the same primary tumors and effu sions but did not receive interleukin 2 and DEX injection were reviewed and classified as the control group. Results Forty patients with solid tumors and 66 patients with lymphoma were further diagnosed with pleural effu sion ascites or pericardial effusion. A total of 85 patients received IL-2 and DEX injection while the remaining 21 did not. The Kaplan Meier analysis revealed a significant difference between the two groups with p Zhang et al. BMC Cancer 2021 21 1302 Page 2 of 8 no coherent management protocol is currently found for and pericardial effusion treatment response and patient pleural effusion ascites and pericardial effusion. It seems outcome. The Institutional Review Boards approved that pleural effusion ascites and pericardial effusion can the collection of patients clinical records. All data were only be resolved with systemic .

• Y khoa - Dược
• BMC Cancer
• Pleural effusion
• Pericardial efusion
• Interleukin 2
• Pediatric cancer
• Intracavitary injections
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study